AUM LifeTech, Inc. presents preclinical developments in lung cancer, Parkinson’s disease and HIV at BIO Digital 2021 | State


img

PHILADELPHIA, June 10, 2021 /PRNewswire/ — AUM LifeTech, Inc., a preclinical biotechnology company, announced today that it has been selected by the National Institutes of Health (NIH) to present an update on their drug development pipeline at 2021 BIO Digital, the most important biotech event. The company has used a self-delivering non-viral RNA targeting technology for therapeutic development in oncology, CNS and infectious diseases.


We are very excited about our recent encouraging preclinical data as we move into the next stages of development.

Veenu Aishwarya, Founder and Chief Executive Officer of AUM LifeTech, will provide an update on their therapeutic programs. “We are honored to be selected by the NIH to present our preclinical developments at BIO 2021. We are very excited about our recent encouraging preclinical data as we move into the next phases of development,” said Aishwarya. “Our therapeutic programs, designed for patients with unmet clinical needs, are now ready for collaborations and strategic alliances to further develop our significantly less risky preclinical assets,” he added.

AUM LifeTech has developed their preclinical cancer immunotherapy pipeline with a focus on lung cancer using their proprietary RNA targeting technology. In addition, their CNS and infectious disease programs include therapeutic development for Parkinson’s disease and HIV, respectively. AUM LifeTech’s HIV preclinical program is funded by the NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Their drug development pipeline is based on self-delivery FANA antisense oligonucleotide (FANA ASO) technology.

BIO Digital is planned June 10-11 & 14-18, 2021, and AUM LifeTech’s therapeutic developments and insight into their gene silencing technology and preclinical research will be available to registered participants at 9 a.m. ET On June 10th. BIO Digital attendees can watch AUM LifeTech’s presentation as part of the NIH Innovation Zone before live meetings in the BIO One-on-One Partnering™ system begin at 14th of June. To meet AUM LifeTech on BIO Digital, find registration information here.

About AUM LifeTech, Inc.

AUM LifeTech is a Philadelphia-based biotechnology company in the preclinical phase, focused on the development of non-viral gene therapy using RNA-targeted therapies. The company uses its self-delivered RNA-targeting antisense oligonucleotide technology to discover and develop drugs for unmet clinical needs with a focus on genetically defined diseases. AUM LifeTech strives to innovate at the genetic level for a better life. To learn more about our vision and mission to help patients worldwide, our pipeline and technology, visit www.aumlifetech.com or follow us on LinkedIn.

About BIO

BIO is the world’s largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations the United States and in more than 30 other countries. BIO members are involved in the research and development of innovative biotech products for healthcare, agriculture, industry and the environment. BIO also produces the ORGANIC International convention, the world’s largest meeting of the biotechnology industry, together with leading investors and partner meetings held around the world. Subscribe to Good Day BIO.

Contact:

AUM LifeTech, Inc.

E-mail address: communication@aumlifetech.com

Web: www.aumlifetech.com

decision View original content to download multimedia:http://www.prnewswire.com/news-releases/aum-lifetech-inc-to-present-preclinical-developments-on-lung-cancer-parkinsons-disease-and-hiv-at-bio-digital-2021- 301310080.html

SOURCE AUM LifeTech, Inc.

This div height required for enabling the sticky sidebar